plus
therapeutics
announces
formation
scientific
advisory
board
austin
texas
globe
newswire
plus
therapeutics
nasdaq
pstv
company
company
focused
making
positive
impact
patients
lives
today
announced
formation
scientific
advisory
board
sab
appointment
leading
experts
fields
preclinical
drug
development
nanotechnology
sab
guide
advise
company
advances
proprietary
versatile
nanotechnology
platform
developing
innovative
chemotherapeutics
radiotherapeutics
rare
cancers
address
unmet
medical
needs
proud
accomplished
diverse
group
scientific
clinical
experts
inaugural
members
scientific
advisory
board
said
marc
hedrick
president
chief
executive
officer
plus
therapeutics
scientific
perspectives
provide
value
supporting
advancement
plus
scientific
programs
including
lead
investigational
drug
rhenium
nanoliposomes
treatment
recurrent
glioblastoma
help
improve
outcomes
patients
management
team
eager
leverage
group
expertise
optimize
r
clinical
founding
members
sab
include
andrew
brenner
brenner
medical
oncologist
tumor
biologist
focus
drug
development
management
primary
brain
tumors
breast
neoplasms
interests
developing
novel
therapeutics
treatment
malignancy
focus
overcoming
resistance
conventional
therapeutics
experience
includes
navigation
regulatory
processes
including
ind
enabling
studies
authoring
study
protocols
coordinating
multicenter
studies
well
acting
principal
investigator
industry
phase
trials
since
brenner
earned
bachelor
degree
biochemistry
went
earn
doctorate
biological
science
tumor
biology
university
texas
anderson
cancer
center
science
park
received
medical
degree
texas
tech
university
health
science
center
completed
residency
internal
medicine
scott
white
hospital
lubbock
texas
completed
fellowship
hematology
medical
oncology
ut
health
san
antonio
john
mckew
mckew
years
experience
developing
novel
therapeutics
successfully
advanced
therapies
preclinical
clinical
development
currently
chief
operating
officer
lumos
pharma
prior
lumos
pharma
mckew
vice
president
research
atyr
pharma
led
research
team
discovering
advancing
therapeutics
rare
diseases
also
served
acting
scientific
director
national
center
advancing
translational
science
ncats
intramural
group
part
national
institute
health
nih
ncats
lab
work
rare
diseases
public
private
partnerships
led
collaborative
advancement
several
therapeutic
candidates
currently
commercialized
pharmaceutical
companies
mckew
also
adjunct
professor
boston
university
school
medicine
previously
served
chair
elect
chair
immediate
past
chair
american
chemical
society
northeastern
section
publications
granted
patents
mckew
graduated
state
university
new
york
stony
brook
degrees
chemistry
biochemistry
completed
organic
chemistry
university
california
davis
held
research
positions
university
geneva
firmenich
sa
vladimir
torchilin
torchilin
university
distinguished
professor
director
center
pharmaceutical
biotechnology
nanomedicine
northeastern
university
boston
obtained
chemistry
well
polymer
chemistry
chemistry
physiologically
active
compounds
moscow
university
torchilin
joined
mgh
harvard
medical
school
head
chemistry
program
center
imaging
pharmaceutical
research
associate
professor
radiology
since
torchilin
northeastern
university
including
chair
department
pharmaceutical
sciences
research
interests
include
liposomes
micelles
biomedical
polymers
drug
delivery
targeting
pharmaceutical
nanocarriers
experimental
cancer
immunology
published
original
papers
reviews
book
chapters
holds
patents
also
wrote
edited
books
including
immobilized
enzymes
medicine
handbook
targeted
delivery
imaging
agents
liposomes
practical
approach
nanoparticulates
pharmaceutical
carriers
multifunctional
pharmaceutical
nanocarriers
biomedical
aspects
drug
targeting
delivery
protein
peptide
drugs
cancer
plus
therapeutics
plus
therapeutics
nasdaq
pstv
pharmaceutical
company
whose
radiotherapeutic
portfolio
concentrated
radionuclides
several
cancer
targets
central
company
drug
development
unique
nanotechnology
platform
designed
reformulate
deliver
commercialize
multiple
drugs
targeting
rare
cancers
diseases
platform
designed
facilitate
new
delivery
approaches
formulations
safe
effective
injectable
drugs
potentially
enhancing
safety
efficacy
convenience
patients
healthcare
providers
information
may
found
cautionary
statement
regarding
statements
press
release
contains
certain
statements
may
deemed
statements
within
meaning
securities
laws
statements
statements
historical
fact
address
activities
events
developments
intend
expect
project
believe
anticipate
similar
expressions
future
conditional
verbs
would
could
may
occur
future
statements
statements
based
upon
certain
assumptions
assessments
made
management
light
experience
perception
historical
trends
current
conditions
expected
future
developments
factors
believe
appropriate
statements
include
without
limitation
statements
company
potential
facilitate
new
delivery
approaches
formulations
safe
effective
injectable
drugs
potentially
enhancing
safety
efficacy
convenience
patients
healthcare
providers
company
potential
develop
drug
candidates
currently
product
pipeline
company
potential
develop
additional
drugs
outside
current
pipeline
statements
included
press
release
subject
number
additional
material
risks
uncertainties
including
limited
risk
company
able
successfully
develop
product
candidates
leverage
fda
accelerated
regulatory
pathways
risks
described
heading
risk
factors
company
securities
exchange
commission
filings
including
company
annual
quarterly
reports
may
events
future
company
unable
predict
control
business
financial
condition
results
operations
prospects
may
change
future
company
assumes
responsibility
update
revise
statements
reflect
events
trends
circumstances
date
made
unless
company
obligation
federal
securities
laws
investor
contact
peter
vozzo
westwicke
icr
media
contact
terri
clevenger
westwicke
icr
